Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

被引:15
|
作者
Lee, Dae Hyun [1 ,2 ]
Kumar, Abhishek [3 ]
Mohammed, Turab [4 ,5 ]
Peres, Lauren C. [6 ]
Alsina, Melissa [5 ]
Bachmeier, Christina
Blue, Brandon J. [5 ]
Brayer, Jason
Chandrasekhar, Sanjay [2 ]
Cruz, Ariel Grajales [5 ]
De Avila, Gabe
Elmariah, Hany [4 ]
Faramand, Rawan [4 ]
Freeman, Ciara [4 ]
Jain, Michael [4 ]
Khadka, Sushmita [4 ]
Khimani, Farhad [4 ]
Liu, Hien [4 ]
Nishihori, Taiga [4 ]
Oswald, Laura B. [1 ,7 ]
Puglianini, Omar A. Castaneda [4 ]
Shain, Kenneth H. [5 ]
Smith, Eric [4 ]
Baz, Rachid C. [5 ]
Locke, Frederick L. [4 ]
Oliveira, Guilherme H. [1 ,2 ]
Alomar, Mohammed [1 ,2 ]
Hansen, Doris K. [4 ]
机构
[1] Univ South Florida Morsani, Coll Med, Div Cardiovasc Med, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Cardiooncol, Tampa, FL USA
[3] Univ South Florida Morsani, Dept Internal Med, Coll Med, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunoth, Tampa, FL 33612 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
关键词
T-CELL THERAPY; CARDIOVASCULAR EVENTS; ADULTS;
D O I
10.1182/bloodadvances.2023009766
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, & lambda; light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (& GE;grade 2) cytokine release syndrome (CRS) and immune cell-associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.
引用
收藏
页码:4247 / 4257
页数:11
相关论文
共 50 条
  • [31] Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
    Oswald, Laura B.
    Gudenkauf, Lisa M.
    Li, Xiaoyin
    De Avila, Gabriel
    Peres, Lauren C.
    Kirtane, Kedar
    Gonzalez, Brian D.
    Hoogland, Aasha I.
    Nguyen, Oanh
    Rodriguez, Yvelise
    Baz, Rachid C.
    Shain, Kenneth H.
    Alsina, Melissa
    Locke, Frederick L.
    Freeman, Ciara
    Castaneda Puglianini, Omar
    Nishihori, Taiga
    Liu, Hien
    Blue, Brandon
    Grajales-Cruz, Ariel
    Jim, Heather S. L.
    Hansen, Doris K.
    CANCERS, 2023, 15 (19)
  • [32] Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
    Sidana, Surbhi
    Peres, Lauren C.
    Hashmi, Hamza
    Hosoya, Hitomi
    Ferreri, Christopher
    Khouri, Jack
    Dima, Danai
    Atrash, Shebli
    Voorhees, Peter
    Simmons, Gary
    Sborov, Douglas W.
    Kalariya, Nilesh
    Hovanky, Vanna
    Bharadwaj, Sushma
    Miklos, David
    Wagner, Charlotte
    Kocoglu, Mehmet H.
    Kaur, Gurbakhash
    Davis, James A.
    Midha, Shonali
    Janakiram, Murali
    Freeman, Ciara
    Alsina, Melissa
    Locke, Frederick
    Gonzalez, Rebecca
    Lin, Yi
    Mcguirk, Joseph
    Afrough, Aimaz
    Shune, Leyla
    Patel, Krina K.
    Hansen, Doris K.
    HAEMATOLOGICA, 2024, 109 (03) : 777 - 786
  • [33] CHARACTERIZING CELLULAR KINETICS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS- EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
    Wu, F.
    Zheng, X.
    Burnett, J.
    Zhou, J.
    Chen, Y.
    Caia, A.
    Cook, M.
    Kondic, A.
    Lamba, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S52 - S52
  • [34] Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
    Hashmi, Hamza
    Hansen, Doris K.
    Peres, Lauren C.
    Puglianini, Omar Castaneda
    Freeman, Ciara
    De Avila, Gabriel
    Sidana, Surbhi
    Shune, Leyla
    Sborov, Douglas W.
    Davis, James
    Wagner, Charlotte
    Kocoglu, Mehmet H.
    Atrash, Shebli
    Voorhees, Peter
    Simmons, Gary
    Ferreri, Christopher
    Kalariya, Nilesh
    Anderson, Larry D., Jr.
    Afrough, Aimaz
    Dima, Danai
    Khouri, Jack
    McGuirk, Joseph
    Locke, Frederick L.
    Baz, Rachid
    Patel, Krina K.
    Alsina, Melissa
    HAEMATOLOGICA, 2024, 109 (05) : 1514 - 1524
  • [35] CHARACTERIZING EXPOSURE-RESPONSE RELATIONSHIPS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Zhou, J.
    Burnett, J.
    Zheng, X.
    Chen, Y.
    Caia, A.
    Cook, M.
    Kondic, A.
    Lamba, M.
    Wu, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S82 - S82
  • [36] Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France
    Zhang, Wenjie
    Karampampa, Korinna
    Venkatachalam, Meena
    Cotte, Francois-Emery
    Dhanda, Devender
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 243 - 253
  • [37] Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
    Zanwar, Saurabh
    Sidana, Surbhi
    Shune, Leyla
    Puglianini, Omar Castaneda
    Pasvolsky, Oren
    Gonzalez, Rebecca
    Dima, Danai
    Afrough, Aimaz
    Kaur, Gurbakhash
    Davis, James A.
    Herr, Megan
    Hashmi, Hamza
    Forsberg, Peter
    Sborov, Douglas
    Anderson Jr, Larry D.
    McGuirk, Joseph P.
    Wagner, Charlotte
    Lieberman-Cribbin, Alex
    Rossi, Adriana
    Freeman, Ciara L.
    Locke, Frederick L.
    Richard, Shambavi
    Khouri, Jack
    Lin, Yi
    Patel, Krina K.
    Kumar, Shaji K.
    Hansen, Doris K.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [38] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Sidana, Surbhi
    Ahmed, Nausheen
    Akhtar, Othman S.
    Heim, Michael
    Brazauskas, Ruta
    Hansen, Doris K.
    Ferreri, Christopher
    Freeman, Ciara Louise L.
    Afrough, Aimaz
    Anderson, Larry D., Jr.
    Dhakal, Binod
    Dhanda, Devender
    Gowda, Lohith
    Hashmi, Hamza
    Harrison, Melanie
    Kitali, Amani
    Mirza, Sayeef
    Patel, Jinalben
    Patwardhan, Pallavi
    Usmani, Saad Z.
    Patel, Krina K.
    Ganguly, Siddhartha
    Pasquini, Marcelo
    BLOOD, 2023, 142
  • [39] Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
    Yi Lin
    Noopur S. Raje
    Jesús G. Berdeja
    David S. Siegel
    Sundar Jagannath
    Deepu Madduri
    Michaela Liedtke
    Jacalyn Rosenblatt
    Marcela V. Maus
    Monica Massaro
    Fabio Petrocca
    Ashish Yeri
    Olivia Finney
    Andrea Caia
    Zhihong Yang
    Nathan Martin
    Timothy B. Campbell
    Julie Rytlewski
    Jaymes Fuller
    Kristen Hege
    Nikhil C. Munshi
    James N. Kochenderfer
    Nature Medicine, 2023, 29 : 2286 - 2294
  • [40] COST-EFFECTIVENESS OF TALQUETAMAB-TGVS VS IDECABTAGENE VICLEUCEL FOR TRIPLE-CLASS EXPOSED RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Rong, R.
    Tang, T.
    Shi, L.
    VALUE IN HEALTH, 2024, 27 (06) : S10 - S10